FDAnews
www.fdanews.com/articles/197151-favipiravir-shows-early-promise-in-russian-clinical-trial
Russia on map with flag

Favipiravir Shows Early Promise in Russian Clinical Trial

May 15, 2020

The influenza antiviral favipiravir has shown early positive results as a COVID-19 treatment in a Russian trial.

Early data from the study showed that 60 percent of patients who received the treatment tested negative for the virus after five days. The ongoing trial will include 330 patients in 30 Russian medical centers.

The Russian Direct Investment Fund and the ChemRar Group, the company leading the trial, intend to begin commercial deliveries of the drug in Russia by the end of the month.

View today's stories